title: [Depression following use of Imap 1.5 mg].
abstract: Fluspirilene (Trademark Imap) is a depot neuroleptic agent for i.m. injection known for several years. Since it is well tolerated, has substance-specific repository properties and rarely leads to extrapyramidal motorial side effects, it has proved itself efficient for the in- and outpatient treatment of psychoses. Recently however, an extension of its indication has been advocated (as a "weak tranquilizer") to unspecific anxiety and agitation states as well as functional/neurasthenic syndromes. According to our observations, administration of the drug over several weeks in these cases frequently leads to depressive syndromes. Based on three case studies, this paper illustrates the problems involving administration of 1,5 mg Imap in functional/neurasthenic syndromes and discusses the occasional necessity of antidepressive therapy following discontinuation of the neuroleptic medication.
mesh_terms: D000328:Adult; D003866:Depressive Disorder / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005484:Fluspirilene / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009440:Neurasthenia / Q000188:drug therapy; D013141:Spiro Compounds / Q000009:adverse effects*
chemical_list: D013141:Spiro Compounds; D005484:Fluspirilene
vernacular_title: Depressionen nach Gaben von Impa 1,5 mg.